AbbVie Inc.
ABBV
NYSE138.18
AbbVie Inc.
NYSE:ABBV
RECENT
PRICE
138.18
P/E
RATIO
32.14
(PEG:12.25)
P/E RATIO
RELATIVE
TO S&P
1.32
DIV
YLD
3.87%
High:
Low:
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Legends
Stock price
0.55 Beta (1.0 Market)
0
0
0
0
0
0
0
0
0
% total return 06/23:
Stock
S&P
1y.
0
0
3y.
0
0
5y.
0
0
0
Percent shares traded:
0
0
0
- -
- -
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
TTM
Fiscal year
- -
- -
- -
- -
- -
- -
- -
- -
9.00
2.93
3.20
- -
9.90
2.64
2.87
- -
11.04
2.17
3.73
- -
11.66
3.34
3.81
- -
11.84
2.60
3.64
1.61
12.54
1.11
1.85
1.67
14.20
3.20
4.35
2.05
16.10
3.74
4.12
2.33
17.72
3.33
5.92
2.58
22.15
3.85
8.65
3.77
22.49
5.33
8.64
4.30
25.95
2.62
9.51
4.37
31.78
6.53
12.44
5.24
32.78
6.68
13.69
5.67
32.08
4.28
13.40
5.75
Revenue per share
Earnings per share
Free Cash Flow per sh
Dividends per share
- -
- -
- -
- -
0.20
- -
0.28
9.94
0.23
7.74
0.21
2.13
0.31
2.83
0.38
1.09
0.33
2.45
0.30
2.91
0.33
3.20
0.43
(5.71)
0.37
(5.53)
0.45
7.41
0.45
8.71
0.39
9.74
0.30
8.65
CAPEX per share
Book Value per share
- -
- -
1,580
1,580
1,580
1,577
1,587
1,591
1,610
1,593
1,592
1,479
1,479
1,765
1,768
1,771
1,769
Comm.Shares outs.(m)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
16.7
1.0
3.7%
49.7
2.7
3.0%
19.2
1.0
3.3%
16.1
0.7
3.9%
22.4
1.0
3.4%
25.3
1.0
3.9%
14.5
0.6
5.6%
34.4
0.9
4.9%
17.3
0.6
4.6%
22.1
1.0
3.8%
32.1
1.3
3.9%
Avg. annual P/E ratio
P/E relative to S&P500
Avg. annual div. yield
Capital Structure (31/3/23 | Q1)
Total liabilities
$121,241 m.
Total assets
$134,544 m.
Long-term debt
$59,292 m.
Cash and equiv.
$6,711 m.
Goodwill $32,220 m.
Retained earnings $2,393 m.
Common stock 1,764 m. shares
Market Capitalisation
$243,790 m. (as of 11/6/23)
18,380
31.6%
18,790
30.1%
19,960
17.1%
22,859
33.0%
25,638
36.6%
28,216
34.0%
32,753
19.5%
33,266
39.0%
45,804
24.8%
56,197
31.9%
58,054
32.4%
56,741
16.7%
Revenue (m)
Operating margin
1,150
5,275
897
4,128
786
1,774
836
5,144
1,189
5,953
1,501
5,309
1,765
5,687
2,017
7,882
6,471
4,616
8,521
11,542
8,467
11,836
6,749
7,585
Depreciation (m)
Net profit (m)
7.9%
28.7%
22.6%
22.0%
25.1%
8.9%
22.6%
22.5%
24.5%
23.2%
31.3%
18.8%
(9.4)%
17.4%
6.5%
23.7%
(36.0)%
10.1%
11.1%
20.5%
12.1%
20.4%
24.4%
12.8%
Income tax rate
Net profit margin
8,578
14,630
3,363
10,969
14,292
4,492
4,688
10,565
1,742
5,420
29,240
3,945
6,406
36,440
4,636
4,582
30,953
5,097
(294)
35,002
(8,446)
33,934
62,975
(8,172)
(4,488)
77,554
13,076
(7,266)
64,189
15,408
(1,075)
59,135
17,254
(1,102)
59,292
13,274
Working capital (m)
Long-term debt (m)
Equity (m)
26.5%
21.6%
156.9%
19.5%
19.3%
91.9%
13.0%
10.2%
101.8%
13.5%
13.9%
130.4%
12.0%
13.5%
128.4%
11.3%
12.5%
104.2%
17.0%
11.0%
(67.3)%
13.0%
11.5%
(96.5)%
6.5%
3.9%
35.3%
12.3%
10.5%
74.9%
9.2%
8.2%
68.6%
6.6%
7.0%
57.1%
ROIC
Return on capital
Return on equity
Working Capital
2020
2021
2022
Cash assets
8,479
9,776
9,231
Receivables
8,822
9,977
11,254
Inventory
3,310
3,128
3,579
Other
3,562
4,993
4,401
Current assets
24,173
27,928
28,463
Acc. Payable
2,276
2,882
- -
Debt due
8,502
12,495
4,136
Other
17,883
19,817
25,402
Current liab.
28,661
35,194
29,538
100.0%
- -
38.1%
49.8%
(50.0)%
112.8%
36.0%
155.1%
37.6%
148.6%
22.6%
58.5%
1.9%
137.6%
19.2%
54.8%
(66.9)%
51.8%
19.8%
46.4%
15.2%
47.6%
(34.0)%
51.0%
Plowback ratio
Div.&Repurch. to FCF
AbbVie Inc. (US) started trading on January 3, 2013 (cik: 0001551152), operates in the Healthcare sector (Drug Manufacturers—General industry), has 50,000 full-time employees, and is led by Mr. Richard A. Gonzalez. AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Annual rates
(avg rate of change)
Past
5 y.
Past
10 y.
Revenues
16.31%
13.81%
Cash flow
18.14%
26.10%
Earnings
37.44%
32.75%
Dividends
15.94%
16.77%
Book value
-58.36%
-45.16%
Insider trading
Type
Shares
Date
Strom Carrie C
InKind
2,876
05/11/23
Waddell Frederick H
Award
1,450
05/05/23
Tilton Glenn F
Award
1,450
05/05/23
Roberts Rebecca B
Award
1,450
05/05/23
Rapp Edward J
Award
1,450
05/05/23
Fiscal Year Ends
Quarterly Revenue (m)
Full fiscal year
I
II
III
IV
2021
13,010
13,959
14,342
14,886
56,197
2022
13,538
14,583
14,812
15,121
58,054
2023
12,225
- -
- -
- -
- -
Fiscal Year Ends
Earnings per share
Full fiscal year
I
II
III
IV
2021
2.01
0.43
1.80
2.29
6.53
2022
2.54
0.52
2.23
1.40
6.68
2023
0.14
- -
- -
- -
- -
Fiscal Year Ends
Quarterly dividends paid
Full fiscal year
I
II
III
IV
2021
1.31
1.31
1.31
1.31
5.24
2022
1.43
1.42
1.41
1.42
5.67
2023
1.51
- -
- -
- -
- -
06/05/2023
Even Mark Cuban Can’t Fix This Broken Drug System
The Wall Street Journal - Read more...
02/09/2023
Pfizer, Novartis, Merck Executives Say They Are Hunting for Deals Again
The Wall Street Journal - Read more...
02/06/2023
AbbVie Aims for New Drugs to Boost Sales
The Wall Street Journal - Read more...
01/31/2023
Humira Faces Competition From First U.S. Copycat
The Wall Street Journal - Read more...
07/07/2022
Senate Report Hits AbbVie’s Bermuda Tax Structure for U.S. Humira Sales
The Wall Street Journal - Read more...
04/18/2022
J&J Settles With West Virginia in Opioid Suit for $99 Million
The Wall Street Journal - Read more...
02/02/2022
Alphabet, PayPal, AMD, Meta, Starbucks: What to Watch in the Stock Market Today
The Wall Street Journal - Read more...
12/08/2021
Allergan Reaches $200 Million Opioid Settlement With New York Authorities
The Wall Street Journal - Read more...
11/02/2021
Opioid Manufacturers Score Win in California Lawsuit
The Wall Street Journal - Read more...
10/29/2021
Apple, Amazon, Lucid, Chevron: What to Watch in the Stock Market Today
The Wall Street Journal - Read more...
07/30/2021
Amazon, Pinterest, Robinhood, Chevron: What to Watch When the Stock Market Opens Today
The Wall Street Journal - Read more...